Biocure Technology

Biocure Technology Diluted EPS

The Diluted Earnings per Share of Biocure Technology (CURE.X.CN) as of Nov 17, 2026 is -0.03 CAD. In the previous year, Diluted Earnings per Share was -0.17 CAD — a change of -85.24% (higher).

Diluted EPS

-0.03CAD

YoY

-85.24%

Last updated:

Diluted Earnings per Share of Biocure Technology is 2024 -0.03 CAD. Diluted Earnings per Share of Biocure Technology was 2023 -0.17 CAD. It decreases by -85.24% higher compared to the previous year.

The Biocure Technology Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2017
-0.06 CAD
Jan 1, 2018
-0.07 CAD
Jan 1, 2019
-0.05 CAD
Jan 1, 2020
-0.03 CAD
Jan 1, 2021
-0.09 CAD
Jan 1, 2022
-0.12 CAD
Jan 1, 2023
-0.17 CAD
Jan 1, 2024
-0.03 CAD
The Biocure Technology Diluted EPS history
YEARDiluted EPSYoY
-0.03CAD-85.24%
-0.17CAD+41.67%
-0.12CAD+33.33%
-0.09CAD+200.00%
-0.03CAD-38.65%
-0.05CAD-28.92%
-0.07CAD+16.02%
-0.06CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocure Technology Stock analysis

What does Biocure Technology do? Biocure Technology Inc develops and commercializes biosimilar products, focusing on biopharmaceutical technologies for recombinant and ranibizumab applications. The company's products include Interferon Beta, Ranibizumab, and PEG-Filgrastim, targeting chronic lymphocytic leukemia and solid tumor cancers through its own CAR T-cell therapy. Biocure's scientists specialize in developing these therapies, which are sold to healthcare providers and pharmaceutical companies seeking cost-effective alternatives to branded biologics. The firm's commercialization efforts center on biosimilar technologies for cancer treatment, leveraging its expertise in CAR T-cell therapy development. The company generates revenue through the sale of its biosimilar products, including Interferon Beta, Ranibizumab, and PEG-Filgrastim, to healthcare institutions and pharmaceutical partners. These products are marketed as cost-efficient alternatives for cancer treatment, with a focus on chronic lymphocytic leukemia and solid tumor applications. Biocure's development of CAR T-cell therapy for targeted cancer treatment represents a key segment of its revenue stream, alongside its broader biosimilar technology portfolio. Healthcare providers and pharmaceutical companies purchasing these products form the primary customer base for Biocure's commercialized therapies. Biocure Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocure Technology stock

Diluted Earnings per Share of Biocure Technology is -0.03 CAD in 2024.

Diluted Earnings per Share of Biocure Technology changed from -0.17 CAD to -0.03 CAD, representing a -85.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Biocure Technology since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biocure Technology

All Key Metrics — Biocure Technology